The European Commission has granted marketing authorisation to Novo Nordisk for Victoza to treat type 2 diabetes in adults.

The authorisation for Victoza, a once-daily human Glucagon-Like Peptide-1 analogue developed for the treatment of type 2 diabetes, will cover all 27 EU member states.

Victoza is the brand name approved in Europe for liraglutide.

Novo Nordisk executive vice-president and chief science officer Mads Thomsen said that this was an important milestone in the treatment of type 2 diabetes.

“In clinical studies involving more than 6,500 people with type 2 diabetes, Victoza has been shown to have a significant blood glucose-lowering effect and lead to weight loss, while having a low risk of hypoglycaemia. On this background, we are convinced that Victoza is a valuable new treatment option for people with type 2 diabetes,” Thomsen said.

Novo Nordisk will launch Victoza in the UK, Germany and Denmark during summer 2009, and in other European markets during the second half of 2009 and throughout 2010.